Syros Pharmaceuticals, Inc. Syros Pharmaceuticals, Inc.
  • Home
  • Our Coordinated Expression
    • Overview
    • Our Culture, Mission & Values
    • Our Commitment to Diversity, Equity & Inclusion
    • Message from BIO
  • Our People
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Tamibarotene
    • SY-2101
    • SY-5609
    • Expanded Access Policy
  • Clinical Trials
  • Platform
    • Overview
    • What is Gene Control?
    • Publications and Abstracts
  • Patients
  • Investors & Media
  • Partners
  • Careers
  • Blog
  • Contact
Investors & Media

Investors & Media

  • Overview
  • News
    • Email Alerts
    • Press Releases
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Company Info
    • Fact Sheet
    • Profile
    • Leadership
    • Contacts
    • Analyst Coverage
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
    • IRS Tax Form 8937
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Filings
    • Quarterly Reports
    • Proxy
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor & Media Tools
    • Email Alerts
    • Fact Sheet
    • Tear Sheet
    • Contacts
    • RSS News Feed

Press Releases

  • News

  • Email Alerts
  • Press Releases
Sep 7, 2023

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 8, 2023

Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aug 4, 2023

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2023

Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Jul 5, 2023

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 8, 2023

Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference

Jun 1, 2023

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 25, 2023

Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

May 10, 2023

Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update

May 9, 2023

Syros to Present at JMP Securities 2023 Life Sciences Conference

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...29
© 2023 Syros Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Terms of Use Sitemap
twitter logo linkedin logo